Corporate ActionJul 14, 2026, 08:17 AM
Inhibikase Raises $50M via ATM Share Sale for PAH Study
AI Summary
Inhibikase Therapeutics, Inc. announced the sale of 25,000,000 shares of its common stock through its at-the-market (ATM) facility to RA Capital Management, generating gross proceeds of $50 million. This capital infusion is expected to fund operations through the topline data readout of the company's global Phase 3 IMPROVE-PAH clinical study, subject to the full exercise of outstanding Series A and B Warrants.
Key Highlights
- Inhibikase Therapeutics sold 25,000,000 shares of common stock.
- The sale was made through its at-the-market (ATM) facility.
- Gross proceeds from the sale totaled $50 million.
- Shares were sold to RA Capital Management.
- The capital will support operations through topline data readout for the Phase 3 IMPROVE-PAH clinical study.
Price Impact
More from IKT